Search research articles
Contact Us
Filters
Showing results (1-10 of 104) with videos related to
Page
of 11
Sort By:
Continuum (Minneapolis, Minn.)
|
June 5, 2016
Early Relapsing Multiple Sclerosis
David E Jones
Neurology. Clinical Practice
|
August 15, 2018
Disease-modifying therapies for nonrelapsing multiple sclerosis: Costs and benefits of medical intervention
David E Jones
Gastroenterology & Hepatology
|
June 17, 2021
Practical Applications of Biochemistry Results in Primary Biliary Cholangitis
David E Jones
Digestive Diseases (Basel, Switzerland)
|
July 19, 2014
Pathogenesis of primary biliary cirrhosis and its fatigue
Laura Griffiths, David E Jones
Therapeutic Advances in Gastroenterology
|
October 21, 2017
Novel strategies and therapeutic options for the management of primary biliary cholangitis
Amardeep Khanna, David E Jones
Journal of Neurology
|
October 25, 2017
Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Gabriel Pardo, David E Jones
Journal of Neurology
|
September 8, 2017
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Gabriel Pardo, David E Jones
Expert Review of Clinical Immunology
|
August 23, 2014
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety
David E Jones, Myla D Goldman
The New England Journal of Medicine
|
September 13, 2018
Bezafibrate in Primary Biliary Cholangitis
David E. Jones, Vinod S Hegade
Military Medicine
|
January 30, 2013
Traumatic event management in Afghanistan: a field report on combat applications in regional command-south
David E Jones, Patricia Hammond, Kathy Platoni
Page
of 11
Search research articles
Search
Showing results (1-10 of 104) with videos related to
Sort By:
Page
of 11
Continuum (Minneapolis, Minn.)
|
June 5, 2016
Early Relapsing Multiple Sclerosis
David E Jones
Neurology. Clinical Practice
|
August 15, 2018
Disease-modifying therapies for nonrelapsing multiple sclerosis: Costs and benefits of medical intervention
David E Jones
Gastroenterology & Hepatology
|
June 17, 2021
Practical Applications of Biochemistry Results in Primary Biliary Cholangitis
David E Jones
Digestive Diseases (Basel, Switzerland)
|
July 19, 2014
Pathogenesis of primary biliary cirrhosis and its fatigue
Laura Griffiths, David E Jones
Therapeutic Advances in Gastroenterology
|
October 21, 2017
Novel strategies and therapeutic options for the management of primary biliary cholangitis
Amardeep Khanna, David E Jones
Journal of Neurology
|
October 25, 2017
Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Gabriel Pardo, David E Jones
Journal of Neurology
|
September 8, 2017
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Gabriel Pardo, David E Jones
Expert Review of Clinical Immunology
|
August 23, 2014
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety
David E Jones, Myla D Goldman
The New England Journal of Medicine
|
September 13, 2018
Bezafibrate in Primary Biliary Cholangitis
David E. Jones, Vinod S Hegade
Military Medicine
|
January 30, 2013
Traumatic event management in Afghanistan: a field report on combat applications in regional command-south
David E Jones, Patricia Hammond, Kathy Platoni
Page
of 11